Search Results
Mar 31, 2026, 16:45 ET Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
efficacy independent of concomitant GLP-1 receptor agonist use. In Zenkuda-treated patients, the proportion achieving a ≥2-step improvement in DRSS was 60.0% among those using GLP-1 medications versus 64.3% among those not using GLP-1 medications, supporting Zenkuda's efficacy
More news about: Kodiak Sciences Inc.
Mar 31, 2026, 16:35 ET San Antonio Breast Cancer Symposium® fuels $39.6 million impact and advances in cancer care
medical oncology and hematology fellows at UT Health San Antonio — Colton Jones, MD and Daniela Urueta Portillo, MD — shared research on how GLP-1 weight loss medications may influence breast cancer treatment response and side effects."We are extraordinarily proud to partner with
More news about: UT Health San Antonio
Mar 31, 2026, 11:46 ET West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
West. "This expansion increases our global capacity to support drug handling for high-volume injectable therapies, including next-generation GLP-1 treatments. This reinforces West's role as a critical partner in helping to secure patient access to these essential medicines."As demand
More news about: West Pharmaceutical Services, Inc.
Mar 31, 2026, 10:16 ET Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035, Driven by Preventive Healthcare Across North America, Europe & Asia-Pacific - Key Players Nestlé, Abbott, Danone & DSM Lead Innovation
https://www.futuremarketinsights.com/reports/multi-nutritional-supplement-marketGLP-1 Nutritional Support Market: https://www.futuremarketinsights.com/reports/glp-1-nutritional-support-marketAbout Future
More news about: Future Market Insights
Mar 31, 2026, 10:04 ET /C O R R E C T I O N -- AbbVie/
education," said Glen Curran, Senior Vice President Allergan Aesthetics. "Whether patients are experiencing body changes following weight loss with GLP-1 medication, noticing specific areas resistant to diet and exercise, or simply seeking a more sculpted appearance, CoolMonth helps them take the next
More news about: AbbVie
Mar 31, 2026, 08:00 ET Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline
Proceeds will support advancement of the Company's oral small molecule GLP-1 candidate and other novel cardiometabolic programs into clinical developmentBOULDER, Colo., March 31, 2026
More news about: Ambrosia Biosciences
Mar 31, 2026, 07:54 ET RO HELPS PATIENTS SAVE UP TO $1,200 PER YEAR ON WEGOVY® THROUGH COLLABORATION WITH NOVO NORDISK
pushing forward a new model for how life-changing GLP-1 treatments reach patients—more affordably and at scale." Since April of 2025, Ro has worked with Novo Nordisk to help more patients access FDA-approved GLP-1 medications at the best available cash prices. Most recently,
More news about: Ro
Mar 31, 2026, 07:46 ET Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year
weight off.Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.It is not known if Wegovy® injection is safe and effective:to reduce the risk
More news about: Novo Nordisk
Mar 30, 2026, 18:10 ET MENU - ORDER AI Becomes #1 App for GLP-1 Meal Searches on the Apple App Store in the United States
ORDER AI, the AI-powered dining companion helping users choose high-protein, GLP-1 friendly meals in seconds, announced today that it has become the #1 app searched for GLP-1 meal guidance on the Apple App Store in the United States. This milestone reflects
More news about: MENU - ORDER AI
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
enhanced safety profiles, these therapies have the potential to complement and expand upon existing treatment options, including various agonists of GLP-1 receptor, GIP receptor, and GCG receptor. These programs are supported by the Company's antibody discovery platform and Hu-mAtrIxTM AI platform,
More news about: Harbour BioMed
Mar 30, 2026, 09:05 ET Tigermed Announces 2025 Annual Results
including CTRM, CTCM, and Safety Portal, were upgraded with new features during the reporting period. In cutting-edge fields such as weight loss with GLP-1 drugs, the Company is deeply integrating decentralized clinical trials (DCTs) with digital tools, and deployed the Tigermed DCT platform at AKTH Hospital
More news about: Tigermed
Mar 30, 2026, 08:56 ET Tigermed Announces 2025 Annual Results
CTRM, CTCM, and Safety Portal, were upgraded with new features during the reporting period. In cutting-edge fields such as weight loss with GLP-1 drugs, the Company is deeply integrating decentralized clinical trials (DCTs) with digital tools, and deployed the Tigermed DCT platform
More news about: Tigermed
Mar 30, 2026, 08:00 ET Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)
Receiving GLP-1 Agonists for Weight Loss was obtained from an electronic survey of health care professionals in the United States who had experience treating patients with aesthetic concerns associated with GLP-1 agonists.The population of GLP-1 patients seeking
More news about: AbbVie
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
arthritis who also have obesity or overweight. Zepbound is the only FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity management medication.About the TOGETHER-PsA TrialTOGETHER-PsA (NCT06588296)
More news about: Eli Lilly and Company
Mar 27, 2026, 11:00 ET Solving the oxygen problem in cell-based drug delivery
three biologic molecules representing different therapeutic classes and half-lives: an antibody, a hormone and an exenatide, which is a GLP-1-like molecule."In addition to solving the oxygenation and cell density problem, the HOBIT platform is also proof of concept that cell factories
More news about: Rice University
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
"Approximately 30 million patients are projected to be on GLP-1s by 2035. The majority will face discontinuation and significant weight regain. Fractyl stands alone developing the first potential procedural option for post-GLP-1 weight maintenance with pivotal data expected this year."With
More news about: USA News Group
Mar 27, 2026, 09:00 ET The future of skin aging may be found in the kitchen: 2026 American Academy of Dermatology Annual Meeting to highlight latest advancements in skin, hair, and nails
disease, and joint pain. As interest grows in the connection between metabolic health and inflammation — particularly with the widespread use of GLP-1 receptor agonists for weight loss and diabetes — understanding how obesity influences inflammatory skin disease has become increasingly relevant.
More news about: American Academy of Dermatology
Mar 27, 2026, 06:40 ET Shreehas Tambe nombrado CEO y Director General de Biocon Limited con efectos a partir del 1 de abril de 2026
obesidad, oncología e inmunología gracias a un portafolio diferenciado de biosimilares, insulinas, genéricos complejos y péptidos, incluidas las terapias GLP–1.Kiran Mazumdar–Shaw, Presidenta Ejecutiva de Biocon Limited, declaró: «Biocon ha crecido de forma constante anticipándose a
More news about: Biocon
Mar 27, 2026, 06:20 ET Shreehas Tambe übernimmt zum 1. April 2026 die Rolle des Executive Officer und Managing Director bei Biocon Limited
Diabetes, Adipositas und Onkologie durch ein breit aufgestelltes Portfolio aus Biosimilars, Insulinen, komplexen Generika einschließlich Peptiden (GLP-1) eine führende Rolle einzunehmen.Kiran Mazumdar–Shaw, Executive Chairperson von Biocon Limited, erklärte: „Biocon ist stets dadurch gewachsen,
More news about: Biocon
Mar 27, 2026, 06:07 ET Shreehas Tambe est nommé PDG et Directeur Général de Biocon Limited à compter du 1er avril 2026
et l'immunologie grâce à un portefeuille différencié de biosimilaires, d'insulines, de génériques complexes et de peptides, y compris les thérapies GLP–1.Kiran Mazumdar-Shaw, présidente exécutive de Biocon Limited, a déclaré : « Biocon a constamment progressé en anticipant les besoins
More news about: Biocon
Mar 27, 2026, 05:52 ET Shreehas Tambe nominato CEO e Amministratore Delegato di Biocon Limited dal 1° aprile 2026
e immunologia, grazie a un portafoglio differenziato che comprende biosimilari, insuline, farmaci generici complessi e peptidi, incluse le terapie GLP–1.Kiran Mazumdar-Shaw, Presidente Esecutivo di Biocon Limited, ha dichiarato: "Biocon è cresciuta con continuità, anticipando i bisogni
More news about: Biocon
Mar 27, 2026, 05:38 ET Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP–1 therapies.Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said: "Biocon has consistently grown by anticipating
More news about: Biocon
Mar 26, 2026, 19:52 ET FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
with uncontrolled type 2 diabetes, used in combination with a mealtime insulin or in combination with common oral anti-diabetic agents and/or GLP-1 receptor agonists. The clinical program evaluated once-weekly Awiqli® vs. daily basal insulin and demonstrated efficacy in the primary
More news about: Novo Nordisk
Mar 26, 2026, 14:07 ET Lumenis Unveils triLIFT 2.0™: Introducing the Future of Dynamic Muscle Stimulation for Face and Body
folds, and reduced firmness across body areas such as glutes and abdomen. 70% of patients are seeking natural-looking results. In addition, the rise of GLP‑1 medications and aesthetic consequences of rapid weight loss, which include 25-39% muscle mass loss, as well as skin laxity, is further increasing demand
More news about: Lumenis Be. Ltd.
Mar 26, 2026, 09:00 ET EMED RAISES $200 MILLION AT $2 BILLION PLUS VALUATION
curve. GLP-1 medications are the most requested workplace benefit, yet only one in five companies provide the benefit. eMed is changing that.eMed is the gold standard in clinically managed GLP-1 programs for employers. At the core is a fundamental reality: GLP-1s are among
More news about: eMed Population Health